Delivery Order SPE2DR25D1053-SPE2DR26FT827
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $5,237.35 to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Zepbound 5 mg/0.5 mL pen injectors. This competitive, firm fixed-price delivery order is scheduled for completion by September 10, 2025, with performance taking place at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a $41,431.66 firm fixed-price delivery order to AmerisourceBergen Drug Corp on October 22, 2025, for the supply of Zepbound 5 mg/0.5 mL pen injectors. The contract, which represents a child award under AmerisourceBergen's broader pharmaceutical supply agreement with DLA, specifies performance at the contractor's Conshohocken, Pennsylvania facility with an ultimate completion date of October 23, 2025. This delivery order was awarded through open competition...
- The Defense Logistics Agency awarded a $12,575.41 delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Zepbound 5 mg/0.5 mL pen injectors. This firm fixed-price delivery order, which is expected to be completed by September 4, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The award was made on a competitive basis with no...
- The Defense Logistics Agency awarded a $4,273.44 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Zepbound 10 mg/0.5 mL pen injectors with an ultimate completion date of August 18, 2025. This is a non-set-aside competitive award leveraging AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion global pharmaceutical support vehicle that runs through December 2026....
- The Defense Logistics Agency awarded a $10,547.40 firm fixed-price delivery order to AmerisourceBergen Drug Corp on June 18, 2025, for the supply of Zepbound 5 mg/0.5 mL pen injectors. The contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. This prime contract vehicle provides comprehensive global pharmaceutical support to military healthcare...
- The Defense Logistics Agency awarded a delivery order valued at $28,029.17 to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Zepbound 5 mg/0.5 ml pen injectors. This competitively awarded, firm fixed-price delivery order is set to be completed by August 6, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on April 24, 2025, for the supply of Zepbound 5 mg/0.5 mL pen injectors with a ceiling value of $1,143.87 and a completion date of April 25, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at approximately $1 billion through...
- The Defense Logistics Agency awarded a delivery order valued at $5,339.27 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 ml pen injectors on August 1, 2025. This firm fixed-price, non-set-aside contract is scheduled for completion by August 4, 2025, with performance to take place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Zepbound 5 mg/0.5 ml pen injectors, with a ceiling value of $46,729.78 under firm fixed pricing. This is a non-set-aside, competitively awarded contract with an ultimate completion date of August 14, 2025. The work will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under...
- The Defense Logistics Agency (DLA) awarded a $93,571.75 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound 5 mg/0.5 mL pen injectors on September 9, 2025, with completion targeted for September 10, 2025. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $1 billion prime vendor agreement designated SPE2DX and extending through December 2026. The...
- SPE2DR25D1053Indefinite Delivery Contract
- SPE2DR25D1053-SPE2DR26FT827Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $15,814 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 mL pen injectors on November 12, 2025, with an ultimate completion date of November 13, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive $999.99 billion global pharmaceutical support vehicle running through December 2026 that enables the company to supply a broad range of pharmaceutical products and medical supplies to military healthcare programs worldwide. AmerisourceBergen Drug Corp, one of the nation's major pharmaceutical distributors, serves as a critical federal vendor for military and veteran healthcare systems through its extensive portfolio of medical product deliveries. The company demonstrates significant capability in fulfilling federal procurement requirements across multiple therapeutic domains, with its DLA contracts covering specialty medications, vaccines, generic and brand-name drugs, and specialized medical supplies. This particular award for Zepbound, a diabetes medication, reflects AmerisourceBergen's ongoing role in supporting the Defense Health Agency and other government healthcare systems through flexible contract vehicles that provide consistent access to pharmaceutical commodities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $15.8k | 11/12/25 |